Mastodawn

NextCell Reports 7-Year ProTrans Data

NextCell Pharma announces long-term follow-up data from the ProTrans-Repeat study. Results show sustained preservation of insulin production in patients with type 1 diabetes. The high-dose group maintained endogenous insulin levels 7–7.5 years after the first infusion, indicating a durable disease-modifying effect.

#NextCell #diabetes #biotech #lifescience

Tim Street Jan 19

What If Type 1 Diabetes Was Treatable — If You Found It Early Enough?
For most of its history, type 1 diabetes (T1D) has been diagnosed late. By the time symptoms appear, the autoimmune destruction of pancreatic beta cells has usually been underway for years, with a substantial proportion o
https://www.diabettech.com/what-if-type-1-diabetes-was-treatable-if-you-found-it-early-enough/
#Diabetes #BetaCellProtectionTherapies #Diabetes #FutureStates #GPPAD #NextCell #T1DScout #T1DScreening